Evaluation of neuropathic pain occurring after high-dose-rate interstitial brachytherapy of oral tongue

Purpose To recognize neuropathic pain as a complication of high-dose-rate (HDR) interstitial brachytherapy of oral tongue and to evaluate the possible causes of neuropathy. Material and methods Twenty one patients who underwent interstitial brachytherapy for early cancer of oral tongue were evaluated. The patients either underwent primary brachytherapy (42-48 Gy at 3-4 Gy/fraction) or a boost (18-24 Gy at 3 Gy/fraction) after external radiation to 40 Gy. Lingual nerve was the nerve concerned and the sublingual space (SLS) was contoured as its surrogate. Dosimetric parameters were correlated with onset of pain. Results Ten patients out of 21 (47.61%) developed painful neuropathy. Five patients of six (5/6) who underwent primary brachytherapy developed neuropathy. Five out of 15 (5/15) patients who underwent brachytherapy as a boost developed neuropathy. The patients who underwent primary brachytherapy were ten times more likely to develop neuropathy. Among the patients receiving boost treatment, the equivalent dose at 2 Gy/fraction (EQD2) to 2 cc of SLS was higher (39.25 Gy) in the patients who developed pain compared to those without pain (10.29 Gy). Conclusions This is the first report to recognize neuropathic pain as a complication of HDR brachytherapy of oral tongue. Patients undergoing primary brachytherapy were more likely to develop pain. Among other factors like dose to SLS, number of catheters, size of the primary tumor, and the dose rate, only dose to 2 cc of the SLS correlated with onset of pain. The SLS (containing the lingual nerve) may be considered an organ at risk to prevent the occurrence of this complication.

[1]  H. Gray Gray's Anatomy Descriptive and Surgical , 2017 .

[2]  Y. Yoshioka,et al.  High dose rate brachytherapy for oral cancer , 2012, Journal of radiation research.

[3]  S. Arya,et al.  Imaging in oral cancers , 2012, Indian Journal of Radiology and Imaging.

[4]  A. Polo High-dose-rate and pulsed-dose-rate brachytherapy for oral cavity cancer and oropharynx cancer , 2009, Journal of contemporary brachytherapy.

[5]  S. Jamema,et al.  Treatment outcome with low-dose-rate interstitial brachytherapy in early-stage oral tongue cancers. , 2009, Journal of cancer research and therapeutics.

[6]  Vratislav Strnad,et al.  GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  J. Fijuth Is there any place for LDR brachytherapy for head and neck carcinomas in HDR era? , 2009, Journal of contemporary brachytherapy.

[8]  N. Kakimoto,et al.  Brachytherapy for early oral tongue cancer: low dose rate to high dose rate. , 2003, Journal of radiation research.

[9]  J. McGeachie Anatomy of the lingual nerve in relation to possible damage during clinical procedures. , 2002, Annals of the Royal Australasian College of Dental Surgeons.

[10]  N. Malden,et al.  Lingual nerve injury subsequent to wisdom teeth removal – a 5-year retrospective audit from a high street dental practice , 2002, British Dental Journal.

[11]  S. Tung,et al.  High dose rate brachytherapy for early stage oral tongue cancer , 2002, Head & neck.

[12]  S Nag,et al.  The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. , 2001, International journal of radiation oncology, biology, physics.

[13]  Paul Cornes,et al.  Intraoperative Irradiation: Techniques and Results , 1999 .

[14]  A. Fielding,et al.  Lingual nerve paresthesia following third molar surgery: a retrospective clinical study. , 1997, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[15]  T. Inoue,et al.  Phase III trial of high and low dose rate interstitial radiotherapy for early oral tongue cancer. , 1996, International journal of radiation oncology, biology, physics.

[16]  W. Threlfall,et al.  Seven fractions of twice daily high dose-rate brachytherapy for node-negative carcinoma of the mobile tongue results in loss of therapeutic ratio. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  S. McMahon,et al.  Peripheral neuropathies and neurotrophic factors: animal models and clinical perspectives , 1995, Current Opinion in Neurobiology.

[18]  J. Crook,et al.  Effect of dose rate on local control and complications in definitive irradiation of T1-2 squamous cell carcinomas of mobile tongue and floor of mouth with interstitial iridium-192. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  J. Petera,et al.  High dose rate versus low dose rate brachytherapy in the treatment of tongue carcinoma - a radiobiological study. , 2009, Neoplasma.

[20]  A Dutreix,et al.  The Paris system in interstitial radiation therapy. , 1978, Acta radiologica: oncology, radiation, physics, biology.

[21]  David Hepburn,et al.  Gray's Anatomy, Descriptive and Surgical , 1898, Edinburgh Medical Journal.